

MULTIDISCIPLINARY VISUAL DESIGNER

Sapar Tileujanuly

tileujanuly@gmail.com · +7 707 515 61 24 · Almaty, GMT +5
<https://t.me/tileujanuly> · <https://www.instagram.com/tileujanuly/>

Generated 18 August 2026

BRAND IDENTITY

Tanda Coffee

Client: Kelzin Group · Year: 2025 · Scope: HoReCa, Customer Experience


CHALLENGE

The company is a wholesale clothing supplier that offers complimentary coffee to partners visiting its store. However, without a distinct identity, the coffee shop was perceived as just another free amenity. The quality of the beans, the attention to preparation, and the company's investment in partner care remained largely invisible.

SOLUTION

We transformed the coffee shop into a standalone brand with its own logo, visual identity, and branded touchpoints. The new identity communicates that this is not simply free coffee, but a thoughtful, high-quality service created for the company's partners.

By turning the coffee shop into a recognizable and premium experience, the branding reinforces the company's status and reflects its modern, global approach to hospitality and partner service.





TAÑDA  COFFEE







Nidge

Client: Nidge LLC · Year: 2022 · Scope: Brand Identity, Logo, Brandbook


CHALLENGE

Nidge is a Kazakhstan-based technology company specializing in web and mobile application development. Its original logo was created by the founder while he was still a student. As the company grew, this amateur identity no longer reflected the team's expertise, scale, or quality of work. It made the company and its employees appear less experienced than they actually were and offered little visual distinction in a competitive technology market.

SOLUTION

We developed a professional and distinctive visual identity that better represented Nidge as a mature technology company. The new branding strengthened its credibility, shifted client perception away from that of a newcomer, and created a consistent visual language across every brand touchpoint.

When the company later moved into a new office, the brand guidelines also gave the interior designers a clear foundation for translating the character and identity of Nidge.kz into the physical space.







0 - не имеет
1 - имеет

0 - нет, если
не указано
иначе

Представитель профессионала
Актинский отдел профессионала или отдела Профессии профессионала
Актинский отдел и отдел профессионала Профессии.
Профессионал-профессионал и профессионал Профессии.
Профессионал-профессионал и профессионал Профессии.
Профессионал-профессионал и профессионал Профессии.

Профессионал и профессионал
Профессионал









BRAND IDENTITY

Survey Suite

Client: Survey Suite · Year: 2023 · Scope: Logo, Brand Identity, Digital product


CHALLENGE

SurveySuite.io is a survey platform designed to simplify the creation, distribution, and analysis of surveys. As an early-stage startup preparing to launch, the team needed to build a functional MVP quickly and present a credible product to potential investors. Speed was critical, but the company still required a professional identity that could communicate trust, clarity, and technological maturity from day one.

SOLUTION

We developed a complete visual identity for SurveySuite.io in just one week. The system was designed to be clear, flexible, and easy to implement across the MVP without slowing down product development.

This rapid branding process helped the team launch with a cohesive and professional image, complete its working MVP on schedule, and present a stronger, more convincing product to investors.











Ancon

Client: TransTelecom · Year: 2021 · Scope: Naming, Rebranding, Identity

CHALLENGE


The company was originally known as Trans Telecom LLP. Over time, it grew far beyond its telecommunications roots, developing its own engineering capabilities, technical infrastructure, and equipment to deliver large-scale EPC contracts.

However, the original name and identity no longer reflected the company's actual expertise. When approaching clients with EPC proposals, the company often faced questions about why a telecommunications provider wanted to undertake construction projects and whether it had the necessary capabilities. The business had outgrown both its name and its visual identity.

SOLUTION

We created an entirely new brand, including a complete renaming and rebranding of the company as Ancon. The new identity repositioned the business as a capable and established EPC contractor, clearly communicating its expertise across engineering, procurement, and construction.






By removing the limitations of the former telecommunications-focused identity, the rebrand strengthened the company's credibility, supported its expansion into new sectors, and helped Ancon enter markets beyond Kazakhstan.



ancon
EPC COMPANY

PATTERNS AND VISUAL IDENTITY COMPONENTS

Материал	Графическое обозначение	Материал	Графическое обозначение
Металлы		Бетон	
Неметаллические материалы		Стекло	
Дерево		Жидкости	
Камень естественный		Засыпка	
Керамика и силикатные материалы для кладки		Грунт-естественный	




ancon⁺
ENGINEERING




ancon⁺
ENGINEERING




ancon⁺
ENGINEERING



ancon⁺
CONSTRUCTION





ancon⁺
CONSTRUCTION



ancon⁺
CONSTRUCTION





ancon⁺
PROCUREMENT



ancon⁺
PROCUREMENT




ancon⁺
PROCUREMENT













FAMILY SWORD AS A METAPHOR



SYMBOL AND ITS STRUCTURE











BRAND IDENTITY

Rekab


Client: Rekab Ride Sharing · Year: 2020 · Scope: Brand Identity, International Project, Saudi Arabia

CHALLENGE

Entering Riyadh's competitive ridesharing market, Rekab Solutions needed to build recognition and earn passenger trust. Its key advantages—transparent pricing, verified drivers and safe, affordable rides—had to be communicated clearly and consistently.

SOLUTION

We developed a distinctive brand identity and a flexible visual system for Instagram. The system translated Rekab's core benefits into clear, recognizable content while giving the company a consistent foundation for social media communication and future campaigns.



Rekab

METAPHORS AND LOGO COMPONENTS



LOCATION

Geographical position



COMMUNICATION




Message, interaction, interplay





LOCATION PIN



SPEECH BUBBLE



The arabesque is foliate ornament, used in the Islamic world, typically using leaves, derived from stylised half-palmettes, which were combined with spiralling stems.

















BRAND IDENTITY

MedEd Development Program

Client: Cromos Pharma US · Year: 2025 · Scope: Concept Development, Logo Design & Identity System

CHALLENGE

Create a distinct identity for each program while connecting all four within one recognizable learning ecosystem.

SOLUTION

I designed a cohesive logo family using shared geometry, typography and color. Individual symbols give each program its own character while maintaining a clear connection to the Cromos Pharma brand.



LOGO ICON CONSTRUCTION & MEANING



ICON SYSTEM



LOGOTYPE CONSTRUCTION



MAIN GOAL

To develop skills and professional knowledge.

STAGE

Foundation / learning

CORE MOTIVATOR / FEELING

Curiosity & confidence growing

TAGLINE

"Learn. Grow. Connect."

COLORS



VI,3125



Book icon — Learning,
Foundation, Academy

MAIN GOAL

To develop skills and professional knowledge.

STAGE

Foundation / learning

CORE MOTIVATOR / FEELING

Curiosity & confidence growing

TAGLINE

"Learn. Grow. Connect."

COLORS



VI,3125





CROMOS[™]
PHARMA

MAIN GOAL

A comprehensive program that prepares participants for the CRA role. This is the most intensive and demanding of the programs, as it supports a major step in career development.

STAGE

Readiness / transition

CORE MOTIVATOR / FEELING

Momentum & stepping forward

TAGLINE

"Step Forward with Confidence."

COLORS

#273997 #8CB4E8 #FFD600

VI.11.25

II. CRA LAUNCH LOGO



Arrow up —
Momentum
& stepping forward

Medical cross "+" —
Gaining knowledge /
Medicine Symbol

MAIN GOAL

To develop skills and professional knowledge.

STAGE

Foundation / learning

CORE MOTIVATOR /
FEELING

Curiosity & confidence
growing

TAGLINE

"Learn. Grow. Connect."

COLORS



VI.3125



MAIN GOAL

Focused on strengthening day-to-day performance and increasing efficiency in the CRA role.

STAGE

Growth & refinement

CORE MOTIVATOR / FEELING

Progress & strengthening identity

TAGLINE

"Build skills. Shape your future."

COLORS



VI.11.25



Diamond shape —
— Clarity, precision
& self-development

Book form — Learning
& accumulated
expertise

MAIN GOAL

To develop skills and professional knowledge.

STAGE

Foundation / learning

CORE MOTIVATOR / FEELING

Curiosity & confidence growing

TAGLINE

"Learn. Grow. Connect."

COLORS



VI.11.25





CROMOS™
PHARMA

IV. CRA BOOSTER LOGO

MAIN GOAL

Developed to sustain engagement, recognize expertise, and support advanced professional growth.

STAGE

Mastery & leadership

CORE MOTIVATOR / FEELING

Pride, recognition, excellence

TAGLINE

"Lead with Expertise. Excel with Purpose."

COLORS



Mortarboard (academic cap)—
Mastery, achievement & leadership in the CRA field

Star — Excellence, recognition & professional pride

Book form —
Foundation of expertise & lifelong learning

MAIN GOAL

To develop skills and professional knowledge.

STAGE

Foundation / learning

CORE MOTIVATOR /
FEELING

Curiosity & confidence
growing

TAGLINE

"Learn. Grow. Connect."

COLORS



VI.3125



CONSISTENCY

All icons share a unified crest shape and grid, ensuring visual harmony and recognizability across all stages. The consistent blue palette reinforces the medical identity, while accent colors and evolving inner symbols reflect growth – from foundation to mastery.

COLORS

#273997 #0056b3 #ff7f00

VI.1125



VI.1125



The Great Steppe

Client: Kelzin Group · Year: 2022 · Scope: BRAND STRATEGY · NAMING · VISUAL IDENTITY · PRODUCT DESIGN

CHALLENGE

To create Kazakhstan's first outdoor brand from the ground up—from naming and positioning to visual identity and product design. The brand needed to embody the spirit of the Great Steppe: freedom, resilience, vastness, and a deep connection with nature.

SOLUTION

The name Great Steppe became the foundation of the concept. Its values are expressed through functional cuts, clean silhouettes, a nature-inspired color palette, and minimal graphics. Special attention was given to practical, durable materials suited for active movement and changing weather.

Great Steppe combines local identity with contemporary outdoor design, presenting a new image of Kazakhstan—free, functional, and distinctive.







KHAKI

RGB: 60 68 32
CMYK: 69 50 95 55
HEX: 45462A
PANTONE: 5743 C

FORMULA
GUIDE SOLID
COATED



PANTONE®
5743 C

FASHION HOME
+ INTERIORS



PANTONE®
19-0323 TPG
Chive

FOG

RGB: 224 225 207
CMYK: 15 8 23 0
HEX: E0E1CF
PANTONE: 5807 C

FORMULA
GUIDE SOLID
COATED



PANTONE®
5807 C

FASHION HOME
+ INTERIORS



PANTONE®
12-0607 TPO
Green Essence

WHITE

BLACK















THE GREAT STEPPE


42°12'39"N | 80°11'47"E

KELZIN GROUP CUP / EVENT CAMPAIGN

Client: Kelzin Group · Year: 2026 · Scope: NAMING · EVENT IDENTITY · CREATIVE DIRECTION · EXPERIENCE DESIGN · PRODUCTION SUPERVISION

A complete event identity and branded experience developed from the ground up—from naming and creative direction to on-site implementation.

The project included the full visual system, printed and environmental materials, field branding, and a live LED screen interface displaying match results and real-time updates. I supervised production, materials, and printing, and worked on-site to ensure every element functioned consistently throughout the event.





ТОПТЫҚ КЕЗЕҢ: БАРЛЫҚ ОЙЫНДАР

1 ПОЛЕ

FC RUH	0	:	0	PRIME	10:00	11:00	FC RUH	1	:	1	OFFSIDE
ALASH	1	:	0	SUCCESS	10:15	11:15	ALAU	1	:	0	STEPPE
FC RUH	0	:	1	PROFIT FC	10:30	11:30	PROFIT	3	:	0	OFFSIDE
ORTA	0	:	0	STEPPE	10:45	11:45	ULY DALA	0	:	1	STEPPE

2 ПОЛЕ

ALAU	0	:	1	ORTA	10:00	11:00	PROFIT FC	0	:	1	PRIME
QAZAQ POWER	0	:	0	RETAIL UNITED	10:15	11:15	ORTA	1	:	0	ULY DALA
PRIME	0	:	0	OFFSIDE	10:30	11:30	NOMAD	2	:	1	SAUDA UNITED
NOMAD	3	:	0	KOK BORILER	10:45	11:45	ALASH	0	:	0	RETAIL UNITED

3 ПОЛЕ

NOMAD	0	:	0	DINAMO	10:00	11:00	DINAMO	1	:	1	SAUDA UNITED
KOK BORILER	1	:	0	SAUDA UNITED	10:15	11:15	RETAIL UNITED	0	:	1	SUCCESS
ALAU	1	:	1	ULY DALA	10:30	11:30	DINAMO	1	:	0	KOK BORILER
ALASH	0	:	0	QAZAQ POWER	10:45	11:45	SUCCESS	0	:	0	QAZAQ POWER

TURNIR KESTESI



TOPTYQ KEZEŇ

GROUP A

	И	В	Н	П	+/-	О
P.R.O.F.I.T FC	3	2	0	1	4:1	6
PRIME	3	1	2	0	1:0	5
FC RUH	3	0	2	1	1:2	2
OFFSIDE	3	0	2	1	1:4	2

GROUP B

	И	В	Н	П	+/-	О
ORTA	3	2	1	0	2:0	7
ALAU	3	1	1	1	2:2	4
FC STEPPE	3	1	1	1	1:1	4
ULY DALA	3	0	1	2	1:3	1

GROUP C

	И	В	Н	П	+/-	О
NOMAD	3	2	1	0	5:1	7
DINAMO	3	1	2	0	2:1	5
KÖK BÖRILER	3	1	0	2	1:4	3
S.A.U.D.A. UNITED	3	0	1	2	2:4	1

GROUP D

	И	В	Н	П	+/-	О
ALASH	3	1	2	0	1:0	5
SUCCESS	3	1	1	1	1:1	4
QAZAQ POWER	3	0	3	0	0:0	3
RETAIL UNITED	3	0	2	1	0:1	2

1 ПОЛЕ

P.R.O.F.I.T. FC

		МАГАЗИН	ГОЛ
11	АЙТЕНОВ ЕРБОЛАТ	SAQ	-
7	БЕЙБИТ СУЮНОВ	AZART_MENS	-
8	ОРОЗБЕКОВ ДАНИЯР	ОЙБОЙ	-
1	ЖИЕНБАЙ АСЫЛАН	MSW	-
9	ЖАКУПОВ АЛИБЕК	KERKA	-
10	МУХАМБЕТКАЗИМ ЕЛАМАН	BENZO	-
23	ПАНКРАТОВ АЛЕКСАНДР	CITY JEANS	-

FINAL

0:2

ALAU

		МАГАЗИН	ГОЛ
10	МЕИРЖАН	MSQ	-
7	БЕРДИМУРАДОВ АСЛБЕК	MAJORSHOES	-
12	ЖАКИН ДАУРЕН	BOMBA	-
1	КУДАЙБЕРГЕН ЖАКСЫЛЫК	JAKX	-
11	ТОКМЫРЗАЕВ МУХИТ	АКБУЛАК	-
5	МАМБЕТАЛИЕВ БАУРЖАН	РЕАЛ	-
85	СУЛТАНБЕКОВ МАКСАТ	REALIST	-

1 ПОЛЕ

NOMAD

		МАГАЗИН	ГОЛ
13	КУДУСОВ ФАРХАТ	OLIGARCH	-
7	БАҚДАУЛЕТ ЖАСУЗАК	BOKEI STORE	-
10	АБДИРЕИМОВ КАНАТ	KAN	-
9	ДОКТУРБЕКОВ АЗАМАТ	BM BOMOND	-
8	ЗУЛХАРНАЙ АЗАМАТ	MATEO.ALMATY	-
11	АРЗЫКУЛОВ КАДЫРБЕК	КАДЫРБЕК	-
83	АЙБАТЫРОВ БАГДАТ	REALIST	-

3D PLACE

1:0

DINAMO

		МАГАЗИН	ГОЛ
4	РИМОВ ДАУЛЕТ	BENJAMIN	-
10	NURTAS	MENS TRADE	-
90	БАШПАЕВ ЧИНГИЗ	YZY	-
7	ЖУМАДИЛ АСЕТ	RESTYLE	-
11	КУЛПЕЙСОВ ЕРГАЛИ	БАЙМЕН	-
8	НАВРУЗ АБДУРАХМОН	BRUTO	-
-	МЫРЗАХМЕТОВ МАГЖАН	ESTET	-

LIVE: PLAYOFFS

1 ПОЛЕ

1 P.R.O.F.I.T FC

0 SUCCESS

P.R.O.F.I.T FC

2

0

DINAMO

2 ПОЛЕ

0 ORTA

1 DINAMO

P.R.O.F.I.T FC

0

GRAND



FINAL

ALAU

2

1 ПОЛЕ

2(1) PRIME

2(3) NOMAD

NOMAD

0

2

ALAU

2 ПОЛЕ

2 ALAU

0 ALASH



BOMBARDIRLER

ГОЛ САНЫ

I	ОРОЗБЕКОВ ДАНИЯР	5
-	БАҚДАУЛЕТ ЖАСУЗАК	5
II	СУЛТАНБЕКОВ МАКСАТ	3
III	ЖАКИН ДАУРЕН	3
IV	БАШПАЕВ ЧИНГИЗ	2
V	АЙТЕНОВ ЕРБОЛАТ	2



I PLACE / ORYN

ALAU FC

II PLACE / ORYN

PROFIT FC

III PLACE / ORYN

NOMAD FC













JAKX	BOMBA	REAL	MAJORSHOES	TANBA	MSG	4.65	SAQ	4MEN
MENS SHOP 01	BAYSCO	TIMALI	KAN	GOLDMAN	RICAMO	JOKER	YZY	VEER
BELLAZO	ALBERT	MONOTON	BROWN	KELZIN GROUP	BILLION.CO			
GAPPAN	ABAY MEN	CASTO	TANBA	SZ MENS	ACTUAL	MENS LOOK	BAUMA	
BRUTAL	OMAR	BAZA MEN	ERMAN	MATEO.ALMATY	OLIGARCH	BOKEI STORE		
BM BOMOND	QVDYRBEK	REALIST	RESTYLE	BAIMEN	BENJAMIN	BRUTO		
ESTET	BAISAL	RICH MAN	RIDGES	AQ BULAQ	MONSE.ASTANA	BIAI PREMIUM	I'M RICH	
HIRA	MS	XAN STORE	AEN	MEN'S SHOP	ZEN AND ZEN	LIONS		
ZIO	KRU	4MONKEYS	ALTYN ORDA	ASTANA SHOES	FOR MEN	LEGENDA		
SULTAN	MEN'S REPUBLIC	MSW	AZART_MENS	KEPKA	RENZO	OIBOI		
CITY JEANS	AXIMENSSHOP	MOKA	BATO	LONTO_ROOM	MENSS_ZONE			
BLACK FORD	CITY JEANS	OVERMAN	HERO_MAN_ALMATY	BEST MENS WEAR				
ETOR.KASKELEN	MENS TRADE	PALUAN'DAR	SHAMIL_BRAND_020	BLESSED				





REAL MAJORSHOES TANBA MSQ 4.65
BAYSCO TIMALI KAN GOLDMAN RICAMO JOKE
LBERT MONOTON OWN KELZIN GROUP
MEN CASTO TANBA MENS ACTUAL MEN
BAZA MEN ERM ALMATY OLIGARC
QYDYRBEK REAL BAIMEN BEI
RICH MAN RIDGES AC NSE.ASTANA BIAI
XAN STORE S SHOP ZEN AN
4MONKEYS ALTYN TANA SHOES FOR
Y'S REPUBLIC MSW NS KEPKA
AXIMENSSHOP MOKA LOMTO_ROOM
CITY JEANS OVERMA D_MAN_ALMATY
MENS TRADE PA DA SHAMIL_BRAND_O2









EDITORIAL MARKETING CAMPAIGN

Client: Cromos Pharma · Year: 2025-2026 · Scope: SMM, AI, Newsletter Design, Key Visual

80+ EDITIONS · 11K+ SUBSCRIBERS · ONE CONSISTENT VISUAL SYSTEM


An ongoing editorial campaign created to promote the Cromos Clinical Intelligence Report newsletter to a professional audience of over 11,000 subscribers.

The campaign brings together 80+ editions under one consistent visual system. Each banner translates the topic of a new report into a distinctive key visual while maintaining strong recognition across LinkedIn, Instagram, web and digital channels.





ISO 9001:2015 & ICH GCP E6(R3):
Two Standards, One Language of Quality in Clinical Research



FROM OYSTERS TO ORTHOPEDICS:
China's "Bone-02" Bio-Glue Redefines Fracture Repair



CANCER VACCINES 2025, PART I:

The mRNA Revolution




WORLD CANCER DAY 2026

**What Cancer Vaccines Have Already Achieved
in Real Clinical Practice**

CLINICAL RESEARCH IN 2026

What Changed
and Why It Matters



FDA REJECTS REGENXBIO'S HUNTER SYNDROME GENE THERAPY

A Turning Point for the AAV Field?

**A BREAKTHROUGH
IN ONE OF THE DEADLIEST CANCERS?**
What Daraxonrasib Really Changes



RARE DISEASE DAY 2026:
A NEW ECONOMIC REALITY FOR PHARMA



**THE US-UK PHARMA DEAL IS BIGGER
THAN IT LOOKS**

ONE TRIAL ERA

**A NEW STANDARD FOR DRUG APPROVAL
FROM THE FDA**





WORLD LUNG CANCER DAY

Four Breakthroughs Worth Watching in 2026



FD{AI}

**FDA, AI, AND THE FUTURE
OF CLINICAL TRIALS**

GENERATIVE VIDEO CAMPAIGN

Client: Cromos Pharma · Year: 2025-2026 · Scope: CONCEPT DEVELOPMENT · AI ART DIRECTION · MOTION DESIGN · VIDEO EDITING · POST-PRODUCTION

A series of AI-assisted videos created for Cromos Pharma's digital communications. Each piece was developed from concept to final delivery through a hybrid production workflow: GPT was used to generate static visuals, Gemini Omni Flash brought the scenes to life through animation, and Adobe After Effects was used for compositing, timing, transitions, color refinement, and final polish.

The project combined generative tools with hands-on art direction and post-production to create engaging, brand-consistent video content efficiently.


Polaris Clinical Trial

Client: Acsentage · Year: 2025 · Scope: LOGO DESIGN · VISUAL IDENTITY · UX/UI DESIGN · RESPONSIVE WEB DESIGN

A patient-focused digital platform created to introduce the Polaris clinical trial and make complex medical information clear, accessible, and easy to navigate.

The project began with the development of the Polaris logo and a compact visual identity system, which established the foundation for the website's design language. Detailed trial information was simplified through clear content structure, visual storytelling, and custom infographics.

The website also features an interactive pre-screening questionnaire that helps patients understand whether they may be eligible to participate in the trial. The complete experience was adapted across desktop, tablet, and mobile devices to ensure clarity and consistency on every screen.





POLARIS

About the Study

Trial Design

Eligibility

FAQ

For Patients

English

CONTACT US

For Investigators

POLARIS CLINICAL TRIAL

Global Phase 3 Clinical Trial for Olverembatinib in Chronic Myeloid Leukemia – Chronic Phase (CML-CP)

*Olverembatinib is an investigational drug and is not yet approved by the FDA

A Global, Multicenter, Randomized Phase 3 Study of **Olverembatinib vs. Bosutinib** in Patients with CML-CP Previously Treated with ≥ 2 TKIs

CONTACT US



This study evaluates whether Olverembatinib can provide superior molecular responses and tolerability compared to Bosutinib in CML-CP patients with unmet needs.

Mechanism of Action

- Target Profile:** Potent inhibitor of BCR-ABL1, including T315I and other resistant mutants.
- Pharmacology:** High oral bioavailability; half-life ~ 30 hours supports alternate-day dosing.
- Selectivity:** Minimizes off-target kinase inhibition, reducing class toxicities.



Study Type


Global, multicenter, open-label, randomized Phase 3 trial

Participants

333 adults with CML-CP previously treated with ≥ 2 TKIs

Treatment Arms

Trial Design



Part A:

Previously treated with **at least two** approved TKIs, such as imatinib, nilotinib, dasatinib, radotinib, flumatinib, ponatinib, or asciminib.

Part B:

Patients must meet **all three** of the following criteria at screening.

- Previously treated with **at least one** approved TKI, such as imatinib, nilotinib, dasatinib, bosutinib, radotinib, flumatinib, ponatinib, or asciminib.
- Have T315I mutation at screening.
- There are no other effective and/or tolerable therapies available.

Primary Endpoint:

- MMR at 24 weeks

Secondary Endpoints

- MMR at 48 and 96 weeks
- Complete Cytogenetic Response (CCyR)
- Time to and duration of MMR
- Safety and PROs

Key Objectives



Key Inclusion Criteria

- Adults ≥ 18 with CML in chronic phase
- Prior treatment with ≥ 2 TKIs
- No complete response at screening
- Adequate organ function

Key Exclusion Criteria

- History of accelerated or blast phase CML
- Prior use of Olverembatinib or Bosutinib
- Major cardiovascular events or unstable medical conditions

Interested in this trial?

Leave your details below and we will contact you shortly.

Name	Your Name
Surname	Your Surname
Phone Number	+ 0 (000) 000 00 00
Email	your@email.com
Country	Your Country ▼
City	Your City ▼

- ☒ I agree to share my personal data
- ☒ I consent to use of my data for the purposes indicated in the "privacy policy"

SUBMIT

Investigator Support


- Participating investigators will have access to a dedicated support team and detailed trial materials to ensure seamless patient management and data collection.
- This collaborative approach aims to provide comprehensive data while maintaining the highest standards of patient care.



To become a study investigator
or to refer a patient

CONTACT US

Investigating Sites



Country

Your Country

City

Your City

Boston Clinical
Research Center

Dr. Emily Carter
Principal Investigator
+1 (212) 555-0148
emily.carter@nycmedresearch.org

Midwest Oncology Site

Dr. Michael Thompson
Hematologist, PI
+1 (312) 555-0921
m.thompson@plusclinic.com

Dr. Sophia Ramirez

Frequently Asked Questions

What is the purpose of the trial?



Who can join the trial?



Will I have to stop my current treatment?



Is this an inpatient or outpatient study?



What about side effects?



Do I have to pay to participate?



Can I leave the study?



About the Study

Trial Design

Eligibility

FAQ







POLARIS

About the Study

Trial Design

Eligibility

FAQ

English



CONTACT US

For Patients

POLARIS CLINICAL TRIAL

Global Phase 3 Clinical Trial for Olverembatinib in Chronic Myeloid Leukemia – Chronic Phase (CML-CP)

*Olverembatinib is an investigational drug and is not yet approved by the FDA


Overview

Expanding Options for Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Olverembatinib (HQP1351) is being studied in a global Phase 3 clinical trial as a potential new treatment for patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) who have previously received at least two tyrosine kinase inhibitors (TKIs).

This study is designed to evaluate whether Olverembatinib can improve treatment outcomes compared to Bosutinib, a current standard therapy.

CONTACT US



What Makes Olverembatinib Unique?

Olverembatinib is a third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) that targets resistance mutations, including the challenging T315I mutation. By inhibiting these mutations, Olverembatinib may help suppress cancer cell growth and enable deeper molecular responses.

Study Type

Global, multicenter, open-label, randomized Phase 3 trial

Participants

333 adults with CML-CP previously treated with ≥ 2 TKIs

Trial Design



Treatment Arms


Part A:

Previously treated with **at least two** approved TKIs, such as imatinib, nilotinib, dasatinib, radotinib, flumatinib, ponatinib, or asciminib.

Part B:

Patients must meet **all three** of the following criteria at screening.

Previously treated with **at least one** approved TKI, such as



- imatinib, nilotinib, dasatinib, bosutinib, radotinib, flumatinib, ponatinib, or asciminib.
- Have T315I mutation at screening.
- There are no other effective and/or tolerable therapies available.


Primary Endpoint:

- Major Molecular Response (MMR) at 24 weeks

Secondary Endpoints

- MMR at 48 and 96 weeks
- Complete Cytogenetic Response (CCyR)
- Time to MMR and duration of response
- Safety and tolerability
- Patient-reported outcomes

Goals of the Trial



What to Expect as a Participant

Patients will be randomized to receive either Olverembatinib or Bosutinib. Treatment is outpatient and includes regular clinic visits, lab assessments, and monitoring to ensure safety and track disease response.



Is This Study Right for Me?

You may be eligible if you (Select statements that describe you)

Question 1 of 5

Age $\geq$ 18?

Yes

No

Interested in this trial?

Leave your details below and we will contact you shortly.


Name	Your Name
Surname	Your Surname
Phone Number	+ 0 (000) 000 00 00
Email	your@email.com
Country	Your Country
City	Your City

☒ I agree to share my personal data

☒ I consent to use of my data for the purposes indicated in the "privacy policy"

SUBMIT

Participating Sites



Country

Your Country

City

Your City

**Boston Clinical
Research Center**

123 Main Street, Boston, MA
Tel. +1 (555) 123-4567

Midwest Oncology

456 Market Ave, San Francisco, CA
Phone number not available

Chicago Parker Clinic

9 Main Way, Chicago, IL
Tel. +1 (800) 800-0900

NYC Trial Unit

789 Elm Drive, Dallas, TX
Tel. +1 (800) 000-0000

Boston Clinical

123 Main Street, Boston, MA

Frequently Asked Questions

What is the purpose of the trial?



Who can join the trial?



Will I have to stop my current treatment?



Is this an inpatient or outpatient study?



What about side effects?



Do I have to pay to participate?



Can I leave the study?



If you have any questions, feel free to contact us

CONTACT US



About the Study

Trial Design

Eligibility

FAQ



**This section of the website is intended exclusively
for licensed medical professionals
involved in clinical research.**

By proceeding, you confirm that you are a qualified healthcare provider, such as a physician or clinical researcher, with a professional interest in conducting or supporting clinical trials.

If you are not a medical professional, please return to the main site.

**I confirm that I am a licensed medical professional
involved in clinical research.**

YES, I AM A MEDICAL PROFESSIONAL

NO, I AM A PATIENT

Data Management & Biostatistics

Client: K-Research · Year: 2026 · Scope: UX/UI DESIGN · INFORMATION DESIGN · RESPONSIVE WEB DESIGN

A responsive service page presenting K-Research's Data Management and Biostatistics expertise. Complex information was organized into a clear, structured digital experience and adapted across desktop, tablet, and mobile devices.

Link: <https://kresearch.ru/en-data-management-biostatistics/>



DATA MANAGEMENT & BIOSTATISTICS

Measurable efficiency. We take full ownership of the data lifecycle — from EDC/IWRS design to final statistical reporting.

[FREE AUDIT](#)


WE ADDRESS YOUR KEY CHALLENGES

Manage critical risks and delays at key trial stages

Challenge 1

SLOW ECRF SETUP AND UNCLEAR TIMELINES

Start → 5-7 days: EDC for review → 3 weeks: data collection

OUR SOLUTION

EDC ready for review within 5-7 days. Full data collection launch in up to 3 weeks.

Challenge 2

FRAGMENTED DATA, NO SINGLE SOURCE OF TRUTH

EDC + IWRS + Analytics

OUR SOLUTION

Integrated EDC/IWRS and analytics in a single secure environment with 24/7 access

Challenge 3

REACTIVE INSTEAD OF PROACTIVE QUALITY CONTROL

! Risk !! Anomaly !!! Error

OUR SOLUTION

Real-time risk monitoring and early detection of deviations before timelines are impacted.

Challenge 4

NON-TRANSPARENT STATISTICS AND COMPLEX REGULATORY REPORTING

CDISC SDTM ADaM

OUR SOLUTION

End-to-end biostatistical support and preparation of regulatory-ready outputs in CDISC (SDTM, ADaM) formats.

FULL SCOPE OF SERVICES: FROM CRF DESIGN TO REGULATORY SUBMISSION

DATA MANAGEMENT

DESIGN & SETUP

- End-to-end EDC/IWRS development and validation
- CRF Design and Data Management Plan (DMP) Development

MONITORING & QUALITY CONTROL

- Continuous data monitoring and quality oversight
- Medical data review

DATABASE LOCK

BIOSTATISTICS

PLANNING

- Statistical sections of the study protocol
- Statistical analysis strategy development
- SAP development and TLF mock-ups

STATISTICAL ANALYSIS

- Tables, listings, and figures (TLFs)
- Interim and final statistical analyses

REPORTING

PREPARATION

- Data validation and transformation to CDISC (SDTM)
- Database lock preparation and clean data delivery

& SUBMISSIONS

- Clinical Study Report (CSR) preparation
- Regulatory submission support

WE OFFER A COMPLIMENTARY AUDIT OF YOUR PROJECT STATUS

From a data management and biostatistics perspective



INTERACTIVE DASHBOARD & REPORTS

See how your data will look in real time



CUSTOM LAUNCH PLAN

Clear timelines and milestones for your project



STREAMLINING GUIDELINES

Accelerate processes and reduce costs without compromising quality

FREE AUDIT

WHAT YOU GET WITH K-RESEARCH



SPEED & PREDICTABILITY

Data collection begins just 3 weeks from project start



FULL TRANSPARENCY

All data and key metrics (enrollment rate, data quality, safety) available via secure interactive dashboards — anytime



QUALITY-FIRST APPROACH

Proactive risk monitoring instead of post-hoc corrections. Full compliance with ICH GCP and CDISC standards



DEDICATED ACCOUNTABILITY

An experienced project manager as a single point of contact



SCALABILITY

Flexible team and services tailored to study needs — no overpayment

MEASURABLE PERFORMANCE

> 40%

AVERAGE REDUCTION IN eCRF DEPLOYMENT TIME

Thanks to ready-to-use modules

100%

PROJECTS PASS REGULATORY AUDITS

With no critical data findings

< 24h

AVERAGE RESPONSE TIME TO DATA REQUESTS

Enabled by integrated monitoring systems

24/7

ACCESS TO DASHBOARDS

For real-time, data-driven decisions

FREE PERSONALIZED SYSTEM DEMO

IN JUST 30 MINUTES, WE WILL SHOW YOU:

- Real-time dashboards using your data structure
- Our quick-start templates
- Preliminary streamlining guidelines for your current processes

[CONTACT US](#)



K-RESEARCH

[Privacy Policy](#)
Occupational Health & Safety Management System
© 2018-2026 K-Research. All rights reserved.

Patient Education Video Series

Client: Cromos Pharma · Year: 2026 · Scope: AI CONTENT CREATION · MOTION DESIGN · VIDEO PRODUCTION · PATIENT EDUCATION

A series of patient explainer videos designed to make clinical trials easier to understand and less intimidating. The content answered the most common patient concerns in a clear, reassuring format, helping simplify a complex topic quickly and effectively.

The workflow combined GPT-generated static visuals, ElevenLabs voiceover, HeyGen video and subtitles, and Adobe After Effects for graphics and final polish.



Patient Education Video Series

Margulan Platform — Content & Educational Design

Client: EduPlat LTD · Year: 2024-2025 · Scope: Art Direction, Editorial Design, Content Design, Marketing Communications, Social Media Design, Layout & Information Hierarchy

I worked across content, marketing and educational initiatives, developing visual systems for information-heavy materials across multiple formats.

From long-form guides and learning resources to social content and campaign assets, the objective was to create clear visual hierarchy, improve content readability and maintain a consistent brand experience across every touchpoint.



Как сократить **Потери Энергии?**

Чек-лист →



01

Проверяйте свои привычки



Спросите себя: действительно ли это действие полезно или оно забирает энергию?



Откажитесь от выполнения задач, которые не приносят пользы или не приближают к вашим целям.

Как сократить потери энергии?

01 Осознайте потери энергии

- ✓✓ Определите, где и как ваша энергия уходит впустую: бесполезные разговоры, переживания, конфликты и т.д.
- ✓✓ Заведите дневник, чтобы фиксировать любые действия, которые истощают вас эмоционально или физически.

02 Проверяйте свои привычки

- ✓✓ Спросите себя: действительно ли это действие полезно или оно забирает энергию?
- ✓✓ Откажитесь от выполнения задач, которые не приносят пользы или не приближают к вашим целям.

03 Минимизируйте пустые разговоры

- ✓✓ Избегайте бесцельных обсуждений и споров, которые забирают много времени и энергии.
- ✓✓ Старайтесь окружать себя позитивными людьми, которые заряжают вас энергией.



02 Как создать или открыть хранилище

Открытие существующего хранилища

- 1 Нажмите кнопку «Открыть» в строке Открыть папку как хранилище
- 2 Выберите нужную папку с файлами в открывшемся поисковом окне.
- 3 Нажмите «Выбор папки»

Создание нового хранилища:

- 1 Нажмите кнопку «Создать» в строке Создать новое хранилище
- 2 Укажите название нового хранилища в строке Имя хранилища
- 3 Выберите место хранения папки с заметками.
- 4 Нажмите «Создать»

Локальное размещение на жестком диске компьютера:

Obsidian позволяет создавать и работать с несколькими хранилищами. Вы можете открыть каждое хранилище в отдельном окне, однако рекомендуется работать в одном хранилище, чтобы поддерживать связи между всеми вашими заметками.

Рекомендации

На курсе мы будем работать в одном хранилище, чтобы поддерживать единую структуру знаний. Разделение заметок по разным хранилищам может усложнить процесс построения связей между ними.



Расписание открытия доступов к модулям



Obsidian

Январь 2025

Пн	Вт	Ср	Чт	Пт	Сб	Вс
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31		

Февраль 2025

Пн	Вт	Ср	Чт	Пт	Сб	Вс
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28		

События

- 01** **Вводный модуль и Модуль 1**
январь База знаний
- 13** **Модуль 2**
январь Создание заметок в Obsidian
- 20** **Модуль 3**
январь Оформление и структурирование базы знаний
- 27** **Модуль 4**
январь Расширенные способы структурирования базы знаний
- 03** **Модуль 5**
февраль Интеграции в Obsidian и защита базы знаний
- 10** **Модуль 6**
февраль Продвинутое инструменты Obsidian

КАК ИЗБЕЖАТЬ ПОТЕРЬ ПРИ ИНВЕСТИРОВАНИИ?

Практические рекомендации для начинающих
инвесторов от Margulan Venture Partners

Это важно!



Около 95% начинающих инвесторов

Теряют значительную часть своего
капитала еще на старте

Причины таких потерь могут быть разными,
но их можно избежать, придерживаясь
простых правил инвестирования

Ниже описаны ключевые ошибки, которые новички совершают чаще всего

Изучите их, чтобы понять, что приводит к потерям и как их избежать, чтобы защитить свой капитал

01 Отсутствие инвестиционной стратегии и завышенные ожидания



Когда инвестирование осуществляется без четкого плана и с завышенными ожиданиями, процесс становится бессистемным




В результате вложенный капитал теряет свою актуальность, так как выбранные инструменты не обеспечивают ликвидность



Рекомендация



Составьте четкий план и установите реалистичные цели. Это поможет выбрать подходящие активы, снизить риски и повысить шанс на прибыль.



02 Вложение в непроверенные инвестиционные предложения



Недобросовестные проекты и команды часто становятся причиной больших убытков, особенно для начинающих инвесторов.



Рекомендация



Инвестируйте только на основе данных. Анализируйте финансовую отчетность, юридическую структуру, планы развития и достижения команды для оценки надежности проекта.

03 Инвестирование без обучения



Многие новички ошибочно считают, что для успешного инвестирования достаточно иметь стартовый капитал.

Однако инвестирование — это сложный процесс, требующий профессиональных знаний и навыков.



Рекомендация



Начинайте инвестиционную деятельность с изучения этой сферы, чтобы быть готовым к принятию осознанных решений и защищать свой капитал от возможных потерь.



04 Непонимание структуры рисков



Каждое инвестирование несет риски, а игнорирование их ведет к потерям. Высокая доходность часто означает высокий риск, требующий тщательного анализа.



Рекомендация



Перед инвестированием оценивайте риски каждого актива, учитывая макроэкономические факторы. Это поможет минимизировать потери и принимать взвешенные решения.



05 Отсутствие диверсификации



Инвестирование в один актив или сектор повышает риск потерь, делая капитал уязвимым к рыночным колебаниям и отраслевым изменениям.



Рекомендация



Диверсифицируйте портфель, распределяя активы. Это снизит риски и обеспечит стабильность капитала.



Понимание ошибок и ключевых принципов инвестирования — основа защиты капитала и создания надежного портфеля.

Инвестиционное сообщество снижает риски, дает знания и

и инвестиционное сообщество снижает риски, дает знания и опыт, помогая участвовать в перспективных проектах и формировать успешный портфель.



Подайте заявку на консультацию с менеджером MVP

Получите ответы на свои вопросы и начните
инвестировать с уверенностью!



Code of Conduct

Client: Avatariya · Year: 2024 · Scope: Editorial Design · Information Design · Layout Systems · Typography · Visual Hierarchy · Brand Consistency · Document Design · Design Systems

CHALLENGE


The company had five Code of Conduct documents with different layouts, typography and visual styles. The challenge was to bring them into one consistent system while staying within the existing brand guidelines.

SOLUTION

I created a unified editorial system with consistent grids, typography, hierarchy, spacing, navigation and reusable page layouts. This turned five disconnected documents into one coherent and scalable publication system.

IMPACT

The result improved readability and brand consistency while making future updates and new documents faster and easier to produce.




Корпоративный кодекс — это не просто набор правил, а фундамент, на котором строится наша культура.

Он отражает нашу миссию, ценности, принципы, которыми мы руководствуемся каждый день.



Авик
Маскот



ПРОАКТИВНОСТЬ

Мы независимы, умеем принимать решения и несем за них ответственность.

Наше поведение зависит от наших решений, а не от обстоятельств или других людей. Мы не ищем виноватых и не оправдываемся — берем на себя ответственность и решаем задачи.

ИНИЦИАТИВНОСТЬ


Мы проявляем инициативу и отвечаем за результаты.

Если вы предлагаете идею, важно не только её озвучить, но и подготовить качественную презентацию. В 80% случаев вы станете лидером проекта и будете готовы к реализации. Даже если не возглавите проект, ваше участие обязательно.

УВАЖЕНИЕ

Мы делимся опытом, мнениями и рекомендациями

для создания положительного и продуктивного коллектива. Мы не идем по головам ради личной выгоды и не подставляем коллег для достижения своих интересов.



14

Позиционирование бренда:

**Детский активити
рестопарк Avatariya**

Сокращенное название:

Парк «Avatariya Ice World»

Avatariya Ice World; World of rocks;
Water world; Magic forest;

Обращение делиться на
две аудитории:



Дети



Родители

Стилистика обращения:

ДРУЖЕЛЮБИЕ И РАДОСТЬ

Сообщения должны вызывать улыбку и создавать позитивный опыт.

Пример:

«Добро пожаловать в Avatariya, мир веселья и волшебства для всей семьи!»

ПРОСТОТА И ДОСТУПНОСТЬ

Общение должно быть лёгким и понятным как для детей, так и для родителей.

Правила и инструкции четкие, уважительные и ясные.

ИГРИВОСТЬ И ФАНТАЗИЯ

Используем яркие, веселые фразы, пробуждающие чувство приключения.

Пример:

«Готовы к загадочным приключениям и невероятным открытиям? Погружаемся в сказочный мир Avatariya!»

ВНИМАНИЕ К РОДИТЕЛЯМ

Показываем заботу о их нуждах, создавая уверенность в безопасности и радости их детей.

Пример:

«Дорогие родители, мы заботимся о безопасности ваших детей, чтобы ваше время в парке было лёгким и радостным!»

17